| Literature DB >> 33953696 |
Elzbieta Moszczyńska1, Elzbieta Marczak1, Mieczysław Szalecki1,2, Krzysztof Kądziołka3, Marcin Roszkowski3, Patrycja Zagata-Lesnicka4.
Abstract
Background: This study aims to analyze the diagnostic accuracy of bilateral inferior petrosal sinus sampling (BIPSS), the gold standard test for the differential diagnosis of ACTH-dependent Cushing's syndrome (CS) in a group of pediatric patients with Cushing's disease (CD).Entities:
Keywords: BIPSS; Cushing’s disease; adenoma; hypercortisolemia; lateralization; pituitary adenoma
Mesh:
Substances:
Year: 2021 PMID: 33953696 PMCID: PMC8092390 DOI: 10.3389/fendo.2021.650967
Source DB: PubMed Journal: Front Endocrinol (Lausanne) ISSN: 1664-2392 Impact factor: 5.555
BIPSS results in pediatric population with Cushing disease.
| Patient | Pre-oCRH C/P ratio | Post-oCRH stimulation C/P ratio | Tumor location | Treatment outcome | Histopathological confirmation | ||
|---|---|---|---|---|---|---|---|
| MRI | BIPSS basal/CRH stimulation | Surgery | |||||
| 1 | 21.5 | 63.2 | normal | R | R | no relapse | microadenoma |
| 2 | 9.3 | 23.3 | normal | L | C | no relapse | microadenoma |
| 3 | 0.8 | 1.1 | heterogenous | lateralization | C | no relapse | microadenoma |
| 4 | 1.5 | 1.4 | normal | lateralization | L | no relapse | microadenoma |
| 5 | 3.7 | 19.5 | 3mm (L) | L | L | no relapse | microadenoma |
| 6 | 14.9 | 27.0 | heterogenous | R | R | no relapse | microadenoma |
| 7 | 8.3 | 22.4 | 4mm (R) | R | R | 2 x surgery | 1.microadenoma |
| 8 | 1.3 | 5.6 | normal | R | C | 2 x surgery | 1.microadenoma |
| 9 | 94.5 | 750.2 | normal | R | L | no relapse | corticotropin cell hyperplasia, IHC ACTH (+) |
| 10 | 43.4 | 115 | heterogenous | R | R | no relapse | pituitary |
| 11 | 15.8 | 20.3 | heterogenous | R | R | no relapse | microadenoma, IHC ACTH (-) |
| 12 | 30.7 | 303.4 | normal | L | L | 2 x surgery | 1.microadenoma, IHC ACTH (+) |
R, right; L, left; IHC, immunohistochemistry.
IHC staining for ACTH was performed since 2016.
Baseline characteristics and biochemical evaluation of 12 pediatric patients with Cushing’s disease.
| No. | Sex | Age at symptoms onset | Age at the time of diagnosis | Duration of disease | Midnight cortisol (μg/dl) | ACTH (pg/ml)N 10-60 | 24h UFC (μg) | Increase after CRH stimulation | Morning serum cortisol (μg/dl) | |||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ACTH (%) | Cortisol (%) | 0’ | LDDST (48h) | HDDST (48h) | ||||||||
| 1 | M | 15.7 | 16.7 | 5 | 13.3 | 66 | 480.8 (<100) | 43.8 | 47 | N.A. | N.A. | N.A. |
| 2 | F | 9.4 | 10.6 | 1.2 | 12.9 | 51 | 849.8 (4-34) | 437.2 | 107 | 26.8 | 4.8 | 13.1 |
| 3 | M | 7 | 15.2 | 8.2 | 23 | 128 | 322.3 (13-120) | 226 | 96 | 21 | 2.2 | 1.7 |
| 4 | F | 10 | 12 | 2.0 | 17.3 | 44.3 | 605 (8.6-52.4) | 259.2 | 139 | 20.3 | 11.4 | 2.2 |
| 5 | F | 8 | 14.3 | 6.3 | 12.6 | 38 | 220.7 (8.6-52.4) | 29.5 | 50 | 20 | 5.3 | 2.6 |
| 6 | M | 10 | 17 | 7.0 | 13 | 43 | 379.6 (13-120) | 0 | 0 | 18 | 1.6 | 1 |
| 7 | M | 9 | 11.6 | 2.6 | 49.1 | 45 | 626 (8-65) | 35.1 | 12 | 43.9 | 44.3 | 22.8 |
| 8 | F | 6 | 8.5 | 2.5 | 17.8 | 69 | 260.4 (2.1-23) | 41.2 | 50 | 24.2 | 2 | 1.1 |
| 9 | M | 8 | 10.4 | 2.4 | 7.9 | 118 | 201.4 (8-65) | 334.9 | 295 | 11.2 | 0.7 | 0.5 |
| 10 | M | 10 | 11.7 | 1.7 | 11.8 | 80.2 | 839.2 (8-65) | 35 | 20 | 25.9 | 19.7 | 1.9 |
| 11 | F | 6.3 | 7.2 | 0.8 | 10.4 | 30.7 | 944 (2.1-23) | 143.3 | 56 | 30.2 | 23.8 | 20 |
| 12 | F | 7.0 | 11 | 4.0 | 12.9 | 55.2 | 284 (4-34) | 214.1 | 205 | 15.2 | 10.4 | 3.9 |
time interval from the onset of initial symptoms to TSS.
in one patient, neither ACTH nor cortisol increased during CRH test.
Figure 1Presentation of maximal IPS/P ACTH gradient at baseline and after CRH administration (3'-5' and 10') during BIPSS procedure in 12 children.
Figure 2Maximal interpetrosal ACTH ratio during BIPSS in the studied group.
Literature summary of BIPSS outcome in Cushing’s disease in children.
| Study | Study cohort | Mean age; age range (years) | Study duration | Baseline C/P ratio > 2 | Post-CRH/desmopressin stimulation C/P ratio >3 | Compatibility of localization of a microadenoma by BIPSS with surgical location |
|---|---|---|---|---|---|---|
|
| 11 | 12.3 ± 3.9; | 1986-2000 | N.A. | 91% (ratio >2) | 91% |
|
| 25 | 13.4 | 1984-2003 | N.A. | 100% | 73.7%, 94% |
|
| 94 | 13 ± 3.2; | 1982-2004 | 90% | 97% | 60.3% (baseline), 58%(CRH stimulation) |
|
| 48 | 14.9 ± 2.5; 9-19 | 1988-2008 | 89% | N.A. | N.A. |
|
| 41 | 12.3 ± 3.5; 5.7-17.8 | 1960-2001 | 75.9% | 86.2% | 75.8%, 81.8% |
|
| 140 | N.A.; | 1982-2010 | N.A. | 99.3 | 81.8% |
|
| 21 | 12.1; | 1986-2010 | N.A. | N.A. | 74% |
|
| 30 | 8.9; | 1983-2013 | 100% | 100% | N.A. |
|
| 16 | 15.5 ± 2.9; | 2006-2017 | 64.7% | 83.3% | 50% (baseline), 42.9% |
|
| 19 | 14; | 1993-2017 | 84.2% | 94.4% | 60% |
|
| 31 | 11.6; | 2003-2020 | 75% | 83.3% | 58.3%, 66.7% |
baseline ratio criteria ≥ 2.
peak ratio criteria ≥3.
desmopressin stimulation.
total prediction rate (lateralization and no lateralization in case of central adenoma localization).